# Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

> **NCT01844115** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 415 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Vilazodone

## Key facts

- **NCT ID:** NCT01844115
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-30
- **Primary completion:** 2014-03-31
- **Final completion:** 2014-03-31
- **Target enrollment:** 415 (ACTUAL)
- **Last updated:** 2019-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844115, "Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01844115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*